Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
| Status: | Completed |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 4/21/2016 |
| Start Date: | September 2014 |
| End Date: | January 2015 |
A Phase 1, Randomized, Open-label, Cross-over, Single-day Study Of Pf-04937319 To Characterize Relative Bioavailability, Tolerability, And Pharmacodynamics Of Four Oral Formulations In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin
Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three
modified release formulations of PF-04937319 compared with the immediate release
material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.
modified release formulations of PF-04937319 compared with the immediate release
material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.
Inclusion Criteria:
- Adults with type 2 diabetes, on stable background metformin therapy either alone or
in combination with another oral anti-diabetic agent (OAD) excluding
thiazolidinediones (TZDs)
Exclusion Criteria:
- Patients with cardiovascular event within 6 months of screening
- Patients with diabetic complications
- Female subjects who are pregnant or planning to become pregnant
- Subjects with unstable medical conditions (eg, hypertension)
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials